CD274 and non-small cell lung carcinoma: In addition, real-world data indicated that for metastatic NSCLC patients with PD-L1 expression < 1%, the combination of nivolumab, ipilimumab, and chemotherapy showed numerically better treatment responses compared to pembrolizumab plus chemotherapy [30,31].